- X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome
- X4 Pharmaceuticals to Participate in Guggenheim’s Emerging Outlook: Biotech Summit 2026
- X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)